In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Tubular glucose reabsorption is performed by the combined action of Na + /D-glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

These SGLT 2 inhibitors prevent glucose absorption in ... “For some unknown reason the drug also protects the kidney. The drug’s mechanism reduces protein leak into urine.

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 ... its mechanism of action and ...

Top of the agendas was chronic kidney disease (CKD), an area where Boehringer is already making an impact with blockbuster SGLT2 inhibitor Jardiance (empagliflozin). Jardiance was originally ...

In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative ... However, there remains a critical gap in knowledge regarding the precise mechanisms of action, reliable ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

A new study published in Nature Communications reveals a novel approach to mitigating tissue damage caused by Streptococcus ...